Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Mar 21;21(11):3376-9.
doi: 10.3748/wjg.v21.i11.3376.

Proposed case of mesalazine-induced cardiomyopathy in severe ulcerative colitis

Kathryn Fleming  1 , Andrew Ashcroft  1 , Christopher Alexakis  1 , Demitrios Tzias  1 , Christopher Groves  1 , Andrew Poullis  1
Affiliations
Case Reports

Proposed case of mesalazine-induced cardiomyopathy in severe ulcerative colitis

Kathryn Fleming et al. World J Gastroenterol. .

Abstract

Five-amino salicylic acids are recommended for use in the management of inflammatory bowel disease, cardiac complications are a rare although recognised phenomenon. This report aims to highlight this serious but rare adverse reaction. We report here a case of a young man presenting with cardiogenic shock in the context of recent mesalazine treatment in severe ulcerative colitis.

Keywords: Adverse reactions; Cardiomyopathy; Mesalazine; Ulcerative colitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
In the “normal” image (A) and “abnormal” image (B) in the late phase of gadolinium enhanced study. A: No enhancement in noted in the myocardium; B: There is diffuse, heterogeneous enhancement of the left and right ventricular myocardium as well as the interventricular septum in the late phase of gadolinium enhancement study.
See this image and copyright information in PMC

References

    1. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1–V16. - PMC - PubMed
    1. Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn’s disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379–388. - PubMed
    1. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2003;(3):CD000543. - PubMed
    1. Loftus EV, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19:179–189. - PubMed
    1. Tsianos EV, Katsanos KH. The heart in inflammatory bowel disease. Ann Gastroentol. 2002;15:124–133.

Publication types

Substances